/
IMUX
$16.58+$0.65 (+4.08%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$217.4M
14M shares
52-week range
$5.06 – $16.86
98% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-74.22
Immunic, Inc. Common Stock
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
www.imux.com- Employees
- 95
- IPO / List date
- Apr 17, 2014
- HQ
- NEW YORK, X1
Held by traders on TradeandTell
No one on the platform currently holds IMUX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IMUX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-04-27 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded IMUX yet.
